Revenue grew 28%, recurring revenue grew 40%, contracted bookings grew 39% — and the stock fell to a 52-week low. The gap between those facts is the whole story, and it comes down to three federal contracts.
Axon Enterprise reported third-quarter 2026 results on 5 November. The stock fell roughly 9.8% that session, then fell sharply again the following day as analysts cut price targets across the board. By midday on Friday 6 November the shares were trading near $312, down about 18% on the day and setting a 52-week low in the $309–315 region, for a market capitalisation of roughly $25bn.
That is a decline of roughly a quarter across two sessions, from a pre-earnings level near $424. Measured from the 52-week high of $665.07, the stock has more than halved.
The headline miss was real but modest: revenue of $908.6M against a Street consensus around $938M, and non-GAAP earnings per share of $1.72 against roughly $1.88–$1.91 depending on whose consensus you use. Those are misses of about 3% and 9% respectively — not the sort of numbers that usually halve a multiple.
| Metric | Q3 2026 | Q3 2025 | Change | Context |
|---|---|---|---|---|
| Total revenue | $908.6M | $710.6M | +28% | Missed a Street consensus of roughly $938M |
| Software & Services | $437.0M | $305.2M | +43% | The recurring, high-margin half of the business |
| Connected Devices | $471.5M | $405.4M | +16% | Down 6.9% sequentially on seasonality and a slipped deployment |
| └ TASER | $233.0M | $238.0M | −2% | The original franchise, now shrinking year over year |
| └ Personal Sensors | $113.5M | $106.7M | +6% | Body cameras — a mature hardware line |
| └ Platform Solutions | $125.0M | $60.8M | +106% | Includes Dedrone counter-drone; the fastest-growing line |
| GAAP net income | $57.0M | −$2.2M | — | GAAP EPS of $0.68 versus a loss a year earlier |
| Non-GAAP EPS | $1.72 | — | — | Against a consensus near $1.88–$1.91 |
| Adjusted EBITDA | $235.7M | — | +33% | A 25.9% margin — ahead of revenue growth |
| Adjusted gross margin | 59.2% | 62.7% | −350bp | Counter-drone mix, memory costs, new product scaling |
Profitability moved the right way. GAAP operating income was $42.1M against a $2.1M loss a year earlier, GAAP net income was $57.0M against a small loss, and adjusted EBITDA of $235.7M grew 33% — faster than revenue. This was not a quarter in which the business stopped working.
The share price reaction was not about the quarter. It was about the forward number. Axon cut full-year 2026 revenue guidance to roughly $3.61–3.63bn, about 30% growth, from prior guidance implying 32–34%. Fourth-quarter revenue is guided to $990M–$1.01bn.
What makes this cut unusual is how concentrated it is. The company attributes the reduction to three large Federal Dedrone deployments totalling roughly $130M of 2026 revenue that it no longer expects to recognise this year: a roughly $30M deployment that slipped out of Q3, and two totalling about $100M previously expected in Q4. Axon states that had those deployments stayed on schedule, full-year growth would have landed nearly 500 basis points above the new guidance and about 200 basis points above the midpoint of the prior guidance.
That framing is the company’s own, and it is the crux of the disagreement now playing out. If the deployments are genuinely delayed, the revenue reappears in 2027 and this was a timing event. If they are at risk of being re-scoped or lost, the growth algorithm that justified a premium multiple is weaker than believed. Nothing in the quarter settles that question, which is precisely why the market repriced rather than waited.
Axon spent a decade being valued on the predictability of subscription revenue from thousands of police agencies on multi-year contracts. Federal counter-drone procurement is a different business: fewer, larger, lumpier deals whose timing sits with the customer. Platform Solutions grew 106% year over year, and that growth is real — but growth sourced from a handful of large federal programmes does not deserve the same multiple as growth sourced from 126% net revenue retention across a broad installed base. Part of what repriced this week is the market noticing that distinction.
The recurring metrics — the ones that actually describe the subscription platform — improved, and in several cases improved faster than the headline.
| Metric | Q3 2026 | Direction | Why it matters |
|---|---|---|---|
| Annual recurring revenue | $1.75B | +40% YoY | Growing considerably faster than total revenue, which means the mix is still shifting toward software. |
| Net revenue retention | 126% | up from 124% | Existing agencies spent 26% more than a year ago before any new customer is counted. This went up, not down. |
| Future contracted bookings | $15.8B | +39% YoY | Roughly four years of revenue already under contract. Axon expects to fulfil 20–25% of it in the next twelve months. |
| Software & Services growth | +43% | accelerating | The segment that carries a 75% adjusted gross margin grew faster than the company as a whole. |
Net revenue retention of 126% is the number that deserves the most attention, because it is the hardest to manufacture. It says existing customers — police departments and federal agencies already using the platform — spent 26% more than they did a year ago, before a single new logo is counted. That figure went up this quarter, not down. A company losing its grip on its installed base does not post that.
Future contracted bookings of $15.8bn, up 39%, represent roughly four years of revenue already under contract, of which Axon expects to fulfil 20–25% over the next twelve months. For a company whose guidance just disappointed, that backlog is the strongest available argument that the disappointment was about timing.
A fair analysis does not stop at the encouraging metrics. Four things got worse, and the margin and cash items are not explained away by federal timing.
59.2%, down from 62.7% a year ago. Counter-drone hardware carries a structurally lower margin than a TASER or a subscription, so a faster-growing Platform Solutions line mechanically dilutes the blended figure. Memory prices are an additional, external cost pressure.
Negative $18.9M in the quarter, against positive $33.4M a year earlier. Full-year free cash flow guidance was cut to $350–400M from a prior $450M target, which the company attributes mainly to inventory investment.
Down 2.1% year over year. The founding product line is no longer a growth engine. That is not fatal for a company where software is now 48% of revenue, but it removes a cushion.
FY2026 revenue cut to roughly $3.61–3.63B, about 30% growth, from prior guidance of 32–34%. Q4 revenue is guided to $990M–$1.01B.
The gross margin point is the one most likely to persist. Counter-drone systems are hardware with a hardware cost structure, and Platform Solutions is the fastest-growing line in the company. Success in that business mechanically dilutes blended gross margin. That is a different and more durable issue than a slipped contract, and it is not obvious that it reverses.
Alongside results, Axon disclosed an additional $1.2bn investment in Skydio, raising its fully diluted ownership to 37%, and became Skydio’s exclusive public safety distributor in the United States and Canada. Skydio expects roughly $1bn of bookings this fiscal year.
Strategically this is coherent. Drone-as-first-responder programmes — autonomous drones dispatched to emergency calls ahead of officers — are among the clearest expansions available to a company that already sells the cameras, the evidence software and the counter-drone layer to the same buyer. Owning the aircraft supply and the exclusive distribution rights removes a dependency.
The timing is harder. A $1.2bn capital commitment disclosed in the same breath as a free cash flow guidance cut to $350–400M invites a question about capital allocation discipline, particularly given net debt of $1.2bn against $1.7bn of cash and short-term investments versus $2.9bn of notes. This is a company spending heavily into an adjacency at the moment that adjacency delivered its first visible disappointment. Reasonable investors read that in opposite directions, and both readings are defensible.
Axon’s counter-drone position originated with the acquisition of Dedrone, completed on 1 October 2024 for roughly $391.1M for the 79.8% stake it did not already hold. For how this fits the wider sector, see our guide to defence tech and drone stocks.
At roughly $312 and a $25bn market capitalisation, Axon trades at about 100 times trailing earnings and roughly 32 times forward estimates. That spread is not a rounding difference — it is the entire valuation debate.
The gap exists because GAAP earnings are small relative to adjusted earnings, and the largest reconciling item is stock-based compensation, guided at $570–600M for 2026 against revenue of about $3.62bn. That is roughly 16% of revenue, and it exceeds full-year GAAP profitability by a wide margin. An investor who treats stock-based compensation as a genuine economic cost sees a company trading at an extremely high multiple of real earnings. An investor who treats it as a non-cash item sees 32 times forward earnings for a business compounding recurring revenue at 40%.
Both positions have serious adherents and this article does not adjudicate between them. What is worth stating plainly is that the question is not a technicality: at 16% of revenue, the treatment of stock-based compensation changes the answer by several multiples. If you want the mechanics, our guides to reading the P/E ratio and reading an earnings report cover how adjusted and GAAP figures diverge.
The pattern across the sell side was large price target reductions with ratings largely intact — an indication that analysts read the quarter as a timing and multiple problem rather than a broken business. That is their interpretation, not an established fact, and the targets below are their published views rather than this site’s.
| Firm | Rating action | Price target | Stated reasoning |
|---|---|---|---|
| Needham | Buy maintained | $750 → $500 | Flagged risk to the 30%+ normalised five-year bookings estimate |
| Northland | Outperform maintained | $800 → $540 | Reduced revenue estimates |
| RBC Capital | Target cut | $735 → $615 | — |
| Baird | Outperform maintained | $675 → $600 | — |
| Piper Sandler | Overweight maintained | $561 → $540 | Cited the Dedrone delays specifically |
| Craig-Hallum | Downgraded to Hold | $390 | The only rating change among the major reactions |
Note the dispersion: targets published in the same week range from $390 to $615 against a share price near $312. That spread is itself information — it tells you the people who model this company full-time do not agree on what the Dedrone delay means, which is a reasonable signal that confident certainty in either direction is unwarranted.
Recurring revenue grew 40% to $1.75bn, net revenue retention rose to 126%, and contracted bookings reached $15.8bn — roughly four years of revenue already signed. The shortfall was traced to three identifiable federal contracts rather than broad demand weakness, and Axon says the underlying pace would have exceeded prior guidance without them. If those deployments land in 2027, the 2026 miss becomes a deferral and the multiple compression was an overreaction to a timing event.
Blended gross margin fell 350 basis points and the cause — a lower-margin counter-drone mix — grows more severe the more successful Platform Solutions becomes. Free cash flow turned negative and the full-year target was cut while the company committed $1.2bn to Skydio. TASER, the founding franchise, is shrinking. And the growth narrative has quietly shifted from predictable agency subscriptions toward lumpy federal procurement, which deserves a lower multiple even when it works. Stock-based compensation at 16% of revenue means GAAP profitability remains thin.
This article is educational analysis of publicly reported results. It is not investment advice, it does not recommend buying or selling any security, and it contains no price target of our own — the analyst targets above are reported as third-party views. Figures are drawn from Axon’s Q3 2026 shareholder letter and filings; share prices were captured intraday on 6 November 2026 and will have changed. Consider your own circumstances and, where appropriate, a licensed adviser before investing.
Get AI prediction signals, unlimited stock comparisons, portfolio analytics, and personalized watchlists — free for 14 days, no credit card required.
14-day free trial · No credit card required · Cancel anytime
Not ready to sign up? Get one free email a week instead.